Published on March 19th, 2017 | by CRST0
Serodus and CRST published results on effects of SER100 in patients with isolated systolic hypertension
Serodus (Oslo Axess: SER) and Clinical Research Services Turku – CRST Oy are pleased to inform that an article on SER100 has been published in Clinical Pharmacology in Drug Development under the title “Safety, tolerability and antihypertensive effect of SER100, an Opiate Receptor-Like 1 (ORL-1) partial agonist, in patients with isolated systolic hypertension”.
“We are happy that these encouraging results are now published and we could give our contribution also to the publication. This is a good example of how a small but professional study site can have a big impact on patient recruitment. CRST in collaboration with Turku University Hospital recruited 13 out of the 17 patients included into the multinational trial,” says one of the authors, Chief Scientific Officer of CRST, Professor Mika Scheinin.
“SER100 is the first compound Serodus tested in a clinical study, and it is now very encouraging to publish the clinical findings in patients with a condition that is common in elderly people,” says CEO of Serodus, Professor Eva Steiness. “We are really happy with the performance of CRST in this trial and we are looking forward to further collaboration,” Steiness adds.
Abstract of the article:
The purpose of the present study was to evaluate safety, tolerability and effect on systolic blood pressure (SBP) of SER100 in a group of 17 patients with isolated systolic hypertension (ISH) in treatment with at least one antihypertensive drug. Eligible patients were randomized to either SER100 (10 mg) or placebo in a cross-over design. Patients were dosed twice daily during two days. Patients were monitored with ambulatory blood pressure measurement for 12 daytime hours.
There were no serious or severe adverse events. Relative to placebo SER100 induced an average reduction of SBP during the two treatment days of 7.0 mmHg (p = 0.0032), whereas the average reduction of diastolic blood pressure (DBP) over the same period was 3.8 mmHg (p = 0.0011). For patients with ISH, this short-term cross-over study of s.c. SER100 demonstrated an acceptable safety profile and consistent, significant lowering of SBP and DBP. The publication is available here.
Serodus ASA (Oslo Axess: SER) is a Scandinavian drug development company, focusing on new therapeutic products for the treatment of diabetes and diabetic comorbidities with large unmet clinical needs. http://www.serodus.com/
About SER100: SER100 is an OLR-1 receptor agonist and has a new mode and site of action in the treatment of patients with ISH. Ser100 has also demonstrated efficacy in experimental animal models of pulmonary hypertension. SER100 has received approval for orphan drug status in pulmonary arterial hypertension by the FDA.